Table of Contents
1 Industry Outlook 9
1.1 Industry Overview 9
1.1.1 Global Driver for Pharmaceutical Demand: 10
1.1.2 Pharmaceutical spending region wise 10
1.1.3 R&D pipeline in pharmaceutical industry 10
1.1.4 Top pharma drugs by sales in 2017 ($Million) 12
1.2 Total Addressable Market 13
2 Report Outline 15
2.1 Report Scope 15
2.2 Report Summary 15
2.3 Research Methodology 16
2.4 Report Assumptions 16
3 Market Snapshot 18
3.1 Market Definition - Infoholic Research 18
3.2 Segmented Addressable Market (SAM) 18
3.3 Trends of Parkinson Diseases Market 19
3.4 Related Markets 20
3.4.1 Neurosurgical Devices 20
3.4.2 Neurointerventional Devices 21
3.4.3 Over the counter drugs (OTC) 23
4 Market Outline 25
4.1 Pipeline Products of Parkinson Diseases Drugs 25
4.2 Market Segmentation 30
4.3 Porter 5(Five) Forces 31
4.4 PEST Analysis 32
5 Market Characteristics 33
5.1 Market Dynamics of Parkinson Diseases Market 33
5.1.1 Drivers 34
5.1.1.1 Increasing Aging Population 34
5.1.1.2 Increasing Prevalence of Parkinson Diseases 34
5.1.2 Opportunities 36
5.1.2.1 Supportive initiatives from government and other organizations 36
5.1.2.2 Exhaustive Pipeline and Increasing Clinical Trials 37
5.1.3 Restraints 37
5.1.3.1 Expiry of patents for blockbuster drugs and availability of generic drugs 37
5.1.3.2 Complex drug development process 38
5.1.4 DRO - Impact Analysis 38
5.1.5 Key Stakeholders 39
6 Drug Type: Market Size and Analysis 40
6.1 Overview 40
6.2 Levodopa 41
6.3 Dopamine agonists 42
6.4 MAO-B inhibitors 43
6.5 COMT Inhibitor 44
6.6 Anticholinergics 45
6.7 Others 46
7 Regions: Market Size and Analysis 48
7.1 Overview 48
7.2 North America 50
7.2.1 Overview 50
7.3 Europe 51
7.3.1 Overview 51
7.4 APAC 53
7.4.1 Overview 53
7.5 Rest of the World 54
7.5.1 Overview 54
8 Competitive Landscape 56
9 Vendor Profiles 58
9.1 Novartis AG 58
9.1.1 Overview 58
9.1.2 Business Unit 62
9.1.3 Geographic Presence 63
9.1.4 Business Focus 64
9.1.5 SWOT Analysis 64
9.1.6 Business Strategy 65
9.2 GlaxoSmithKline plc 66
9.2.1 Overview 66
9.2.2 Geographic Presence 70
9.2.3 Business Focus 70
9.2.4 SWOT Analysis 71
9.2.5 Business Strategy 71
9.3 F.Hoffmann-La Roche Ltd. 72
9.3.1 Overview 72
9.3.2 Business Unit 75
9.3.3 Geographic Presence 76
9.3.4 Business Focus 77
9.3.5 SWOT Analysis 77
9.3.6 Business Strategy 78
9.4 AbbVie Inc. 78
9.4.1 Overview 78
9.4.2 Geographic Presence 81
9.4.3 Business Focus 81
9.4.4 SWOT Analysis 82
9.4.5 Business Strategies 82
9.5 Merck & Co.' Inc. 83
9.5.1 Overview 83
9.5.2 Business units 84
9.5.1 Geographic Revenue 85
9.5.2 Business focus 86
9.5.3 SWOT analysis 86
9.5.4 Business strategies 87
9.6 Teva Pharmaceutical Industries Ltd. 88
9.6.1 Overview 88
9.6.2 Business Unit 90
9.6.3 Geographic Presence 91
9.6.4 Business focus 92
9.6.5 SWOT analysis 92
9.6.6 Business Strategy 93
9.7 Valeant Pharmaceuticals International Inc. 93
9.7.1 Overview 93
9.7.2 Business Unit 96
9.7.3 Geographic Presence 97
9.7.4 Business Focus 97
9.7.5 SWOT Analysis 97
9.7.6 Business Strategy 98
10 Companies to Watch For 99
10.1 Boehringer Ingelheim GmbH 99
10.1.1 Overview 99
10.1.2 Highlights 99
10.2 Amneal Pharmaceuticals' Inc. 101
10.2.1 Overview 101
10.3 Wockhardt 102
10.3.1 Overview 102
10.3.2 Highlights: 102
10.4 STADA Arzneimittel AG 102
10.4.1 Overview 102
10.4.2 Highlights 103
10.5 Pfizer Inc. 104
10.5.1 Overview 104
10.5.2 Highlights 105
10.6 Sun Pharmaceuticals 106
10.6.1 Overview 106
10.6.2 Highlights 107
Annexure 108
Abbreviations 108